Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Share-based Compensation (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Share-based Compensation readings, the most recent being $582000.0 for Q4 2024.

  • On a quarterly basis, Share-based Compensation rose 5.82% to $582000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $2.4 million, a 32.99% increase, with the full-year FY2025 number at $2.6 million, up 12.38% from a year prior.
  • Share-based Compensation hit $582000.0 in Q4 2024 for Unicycive Therapeutics, down from $605000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $929000.0 in Q3 2023 to a low of $144000.0 in Q2 2022.
  • Median Share-based Compensation over the past 3 years was $406000.0 (2022), compared with a mean of $417833.3.
  • Biggest five-year swings in Share-based Compensation: plummeted 50.34% in 2023 and later soared 345.14% in 2024.
  • Unicycive Therapeutics' Share-based Compensation stood at $197000.0 in 2022, then surged by 179.19% to $550000.0 in 2023, then increased by 5.82% to $582000.0 in 2024.
  • The last three reported values for Share-based Compensation were $582000.0 (Q4 2024), $605000.0 (Q3 2024), and $641000.0 (Q2 2024) per Business Quant data.